GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-05-05| LicensingPartnerships

J&J Puts Up $245 Million for Two Promising Autologous CAR-T Candidates

by Reed Slater
Share To

After limited activity in the CAR-T therapy space, Johnson & Johnson’s Janssen Biotech Inc. is jumping right back into the arena with a sizable partnership with Cellular Biomedicine Group Inc. Janssen is laying down $245 million upfront in exchange for two of Cellular Biomedicine’s autologous CAR-T therapy candidates.

Related article: Astellas Trains Sights On Iveric Bio In $5.9 Billion Acquisition

The CAR-T Candidates in Question

Both of Cellular Biomedicine’s autologous CAR-T therapy candidates focus on treating relapsed or refractory non-Hodgkin’s lymphoma (NHL) with a particular emphasis on relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Accounting for about a third of B-cell lymphomas globally, DLBCL is the most common type of aggressive lymphoma. 

The first candidate in the deal is C-CAR039, a bispecific CAR-T therapy targeting CD19 and CD20 antigens. So far, the FDA has already granted the therapy Investigational New Drug (IND) clearance and Fast Track Designation to treat relapsed or refractory DLBCL. C-CAR039 is currently in a Phase 1b study evaluating the therapy in treating relapsed or refractory DLBCL in the U.S.

Details are a bit scanter on the other candidate, C-CAR066, but we know it is a CAR-T therapy targeting CD20 antigens. The therapy has also received IND clearance from the FDA, and a Phase 1b study is set to begin in the second half of this year. 

Terms of the Deal

Janssen said it would pay a whopping $245 million upfront for the two autologous CAR-T therapy candidates and their exclusive worldwide rights, excluding China. Still, the company can negotiate for commercialization rights in China later. 

In addition to the upfront payment, Cellular Biomedicine could gain additional payments contingent upon certain development, regulatory, and sales milestones. The company could also pull in some extra cash from tiered royalty sales if the candidates make it to the market. 

Sen Zhuang M.D., Ph.D., Vice President of Clinical Research and Development at Janssen, said, “We are committed to advancing the science and treatment of B-cell malignancies, especially in DLBCL where deeper responses and long-term remissions represent a persistent unmet need. A tenet to our continued innovation is a focus on accelerating the development of cell therapies as we strive to profoundly transform patient outcomes and, ultimately, progress potentially curative regimens.”

With two new CAR-T therapies under its wing, Janssen is looking to compete with some of the best in the arena. The two new candidates will round off Janssen’s pipeline nicely, adding to the company’s other autologous CAR-T therapy, Carvykti. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Johnson & Johnson Under Fire Again as Legal Action Over Alleged Talc-Cancer Link Moves to the UK
2025-02-05
Posdinemab Becomes J&J’s Second FDA Fast Track Designation Targeting Phosphorylated Tau in Alzheimer’s Disease
2025-01-09
The Boldest Business Matchmaking of 2024: A Look at the Top M&A Activity
2025-01-02
LATEST
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top